The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksETX.L Share News (ETX)

  • There is currently no data for ETX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

e-Therapeutics Loss Widens As It Continues Pipeline Development

Mon, 12th May 2014 11:49

LONDON (Alliance News) - e-Therapeutics PLC Monday posted a widened pretax loss for 2013 as it continued to invest and develop its pipeline of products.

The pharmaceutical company posted a pretax loss of GBP6.1 million, widened from GBP5.0 million, as it upped its research and development expenses.

The company is not yet revenue producing.

E-Therapeutics raised GBP40 million in March 2013 through a share placing, which it said will support the advancement of its compounds to Phase II clinical testing. As a result of this fund raising the company expects its discovery and development plans to be supported into 2019, even if it doesn't have any income from partners.

Its cancer drug candidate ETS2101 underwent two Phase I trials during the year; the company said that further details from these trials are expected later in the year. It intends to complete the mid-stage trials for the drug during the year. In January the company temporarily halted recruitment of its brain cancer trials in the UK and US trials due to drug supply issues. However, it resumed recruitment in March in the UK and in the US in May.

Following the year end it began a further Phase I study with ETS2101 treatment, which it expects to complete in the fourth quarter of 2014.

It said that the product is "at present, the most promising candidate to deliver material for our shareholders." The company said it remained on track to complete a programme of efficacy trials for the compound in time to secure one or more licensing deals by 2018, if data is supportive.

Results from the Phase IIb trial of ETS6103 for the treatment of severe depression will be available in 2015, it said.

E-Therapeutics plans to add new candidates to its pipeline and advance a small number of them through preclinical and early clinical development during 2014, it said.

Shares in E-Therapeutics were trading up 4.9% at 36.44 pence Monday.

By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews

Copyright 2014 Alliance News Limited. All Rights Reserved.

More News
20 Mar 2018 16:14

UK Earnings, Trading Statements Calendar - Next 7 Days

Wednesday 21 March KingfisherFull Year ResultsAlpha FXFull Year In SportFull 22

Read more
9 Jan 2017 08:49

E-Therapeutics Hires Amgen Director As New Chief Executive

Read more
6 Oct 2016 11:23

DIRECTOR DEALINGS: e-Therapeutics Non-Executive Acquires Shares

Read more
14 Sep 2016 11:23

e-Therapeutics Development Director Steve Self To Step Down

Read more
13 Jul 2016 09:13

E-Therapeutics Chairman Takes On Executive Duties As CEO Steps Down

Read more
1 Jun 2016 08:03

e-Therapeutics Offer For Searchbolt Now Wholly Unconditional

Read more
25 May 2016 08:18

e-Therapeutics Focused On Validation Of Drug Discovery Platform

Read more
18 May 2016 15:05

AGM, EGM Calendar - Week Ahead

Read more
12 May 2016 11:13

DIRECTOR DEALINGS: E-Therapeutics Non-Executive Acquires Shares

Read more
11 May 2016 09:06

e-Therapeutics To Buy Searchbolt For GBP2.3 Million (ALLISS)

Read more
22 Mar 2016 11:40

E-Therapeutics Loss Widens As Active Projects Increase

Read more
15 Mar 2016 16:15

Earnings, Trading Statements Calendar - Week Ahead

Read more
15 Feb 2016 10:43

WINNERS & LOSERS SUMMARY: Reckitt Benckiser Results Please Investors

Read more
15 Feb 2016 09:45

E-Therapeutics depression drug trials miss targets

(ShareCast News) - Drug trials results for e-Therapeutics' depression treatment were not as successful as had been hoped, sending shares in the company sharply lower. Phase IIb clinical trials of the company's ETS6103 product did not achieve the aim of matching the efficacy of existing tricyclic ant

Read more
15 Feb 2016 08:20

E-Therapeutics Shares Drop As ETS6103 Trials Miss Primary Endpoint

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.